Huntington's Disease Drug Development: A Phase 3 Pipeline Analysis
Huntington's Disease (HD) is a severely debilitating neurodegenerative disorder in which sufferers exhibit different combinations of movement disorders, dementia, and behavioral or psychiatric abnormalities. The disorder is a result of a trinucleotide repeat expansion mutation that is inherited...
Saved in:
Main Authors: | Hannah J. Van de Roovaart (Author), Nguyen Nguyen (Author), Timothy D. Veenstra (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Huntington's Disease
by: J Gordon Millichap
Published: (1989) -
Genetic analysis of polymorphisms in the kalirin gene for association with age-at-onset in European Huntington disease patients
by: Tsai Yu-Chun, et al.
Published: (2012) -
Genetic Testing in Huntington's Disease
by: J Gordon Millichap
Published: (1997) -
Improving the Drug Development Pipeline for Mycobacteria: Modelling Antibiotic Exposure in the Hollow Fibre Infection Model
by: Arundhati Maitra, et al.
Published: (2021) -
Supplemental Treatment for Huntington's Disease with miR-132 that Is Deficient in Huntington's Disease Brain
by: Masashi Fukuoka, et al.
Published: (2018)